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Abstract
Background and Aim: Allergic bronchopulmonary aspergillosis (ABPA) is classified radiologically based on the findings of
central bronchiectasis (CB) and other radiologic features (ORF). However, the long-term clinical significance of these
classifications remains unknown. We hypothesized that the immunological activity and outcomes of ABPA could be
predicted on HRCT chest finding of high-attenuation mucus (HAM), a marker of inflammatory activity. In this study, we
evaluate the severity and clinical outcomes of ABPA with different radiological classifications.
Methods: Patients were classified based on CT chest findings as: (a) serologic ABPA (ABPA-S) and ABPA-CB; (b) ABPA-S,
ABPA-CB, and ABPA-CB-ORF; and, (c) ABPA-S, ABPA-CB and ABPA-CB-HAM. The clinical, spirometric and serological (total
and A fumigatus specific IgE levels, eosinophil count) severity of the disease and clinical outcomes in various classifications
were analyzed.
Results: Of the 234 (123 males, 111 females; mean age, 34.1 years) patients, 55 (23.5%) had normal HRCT, 179 (76.5%) had
CB, 49 (20.9%) had HAM, and 27 (11.5%) had ORF. All immunological markers were consistently higher in the HAM
classification, while in other classifications these findings were inconsistent. On multivariate analysis, the factors predicting
frequent relapses were presence of HAM (OR 7.38; 95% CI, 3.21–17.0) and CB (OR 3.93; 95% CI, 1.63–9.48) after adjusting for
ORF.
Conclusions: The classification scheme based on HAM most consistently predicts immunological severity in ABPA. Central
bronchiectasis and HAM are independent predictors of recurrent relapses in ABPA. Hence, HAM should be employed in the
radiological classification of ABPA.
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Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a complex
immunological disorder that commonly complicates the course of
patients with asthma and cystic fibrosis. The disease occurs
secondary to antigens released by Aspergillus fumigatus,a n
ubiquitous fungi that colonizes the tracheobronchial tree in these
patients.[1,2] The condition clinically presents with poorly
controlled asthma, hemoptysis, weight loss and fever. The
Rosenberg-Patterson criteria are most often used for diagno-
sis.[3,4] High-resolution computed tomography (HRCT) of thorax
is the imaging modality of choice for the diagnosis of ABPA. The
findings on HRCT chest include central bronchiectasis (CB), high-
attenuation mucus (HAM), air trapping (mosaic attenuation) and
centrilobular nodules. The prevalence of ABPA in asthma is as
high as 19% whereas the prevalence in cystic fibrosis ranges from
6–10%.[2,5] The first case of ABPA was reported in 1952 by
Hinson from the United Kingdom (UK)[6] whereas in the United
States (US) it was identified in 1967.[7] There was an initial belief
that the disorder is rare in North America[8] but subsequent
reports disproved this myth.[9,10] In fact, amongst the four largest
series of ABPA in the world (111 cases [UK][11]; 118 cases
[US][4]; 155 cases [India][12], 164 [India][13]), one is from the
United States.
There are patients of ABPA who otherwise fulfill all diagnostic
criteria, but lack demonstrable abnormalities on CT chest. They
are labeled as seropositive ABPA (ABPA-S) compared with the
more common presentation with CB (ABPA-CB).[14] Another
CT classification scheme categorizes ABPA into mild (ABPA-S),
moderate (ABPA-CB) and severe (ABPA-CB with other radiologic
findings [ABPA-CB-ORF]).[15] The active inflammatory compo-
nent of ABPA clinically manifests as excess mucus secretion and
radiologically as mucoid impaction.[16] On HRCT images, the
CT attenuation of mucoid impaction in ABPA is similar to or less
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values, 10–40).[17,18,19] However, in many patients, mucoid
impaction manifests with high attenuation CT values (CT
Hounsfield values, 70–170),[12,18,20] and is visually denser than
the paraspinal skeletal muscle.[12,18,20,21,22,23,24] The criteri-
on for HAM is based on the visual appearance of the density of
mucus being greater than the paraspinal skeletal muscle. The
corresponding high CT attenuation values wherever available
further strengthens the diagnosis. The clinical importance of HAM
lies in the fact that it has been shown to be associated with
recurrent relapses.[12,25]
Over the last two decades there is an increased awareness that
CT findings can predict outcomes in many pulmonary disorders
including CF.[26,27,28,29] We hypothesized that the presence of
HAM on CT chest at diagnosis would not only correlate with
immunological severity, but could also predict outcome in ABPA.
Herein, we assess the severity of the disease and clinical
significance of different radiological classifications based on
HRCT chest findings, and also propose a new radiologic
classification for ABPA.
Materials and Methods
The present study is a post hoc analysis of prospectively
collected data, and includes 234 consecutive patients of ABPA
diagnosed between January 2004 and December 2008 and
followed till December 2009. The clinical characteristics of 205
patients have been previously described. [12,25,30] The study was
approved by the Institute Ethics Committee, PGIMER, Chandi-
garh, and a written informed consent was taken from all patients.
In our Chest Clinic, all patients with asthma (except those with
glucocorticoid intake more than three weeks in the preceding six
months) are screened for Aspergillus sensitization using an
intradermal skin test. Patients who demonstrate immediate
cutaneous hyperreactivity to Aspergillus antigen are further
investigated for ABPA with IgE levels (total and A fumigatus
specific), eosinophil count, Aspergillus precipitins and HRCT chest.
The detailed methodology has been previously describ-
ed.[12,25,30] Patients are diagnosed as ABPA if they meet both
the following criteria: (a) total IgE levels .1000 IU/mL; (b)
A fumigatus specific IgE levels .0.35 kUA/L; and, two of the
following criteria: (a) presence of serum precipitins against
A fumigatus; (b) radiographic pulmonary opacities (fixed/transient);
(c) absolute eosinophil count .1000 cells/mL; (d) central bronchi-
ectasis on HRCT.[12,25,30,31]
The HRCT of the chest was categorized for the presence and
extent of bronchiectasis.[32] Bronchiectasis was classified as
‘central’ when confined to the medial half (point midway between
Table 1. Baseline characteristics including spirometry,
serological and HRCT findings (n=234).
Demographic details
Age (years), mean (SD) 34.1 (12.5)
Male Gender, No. (%) 123 (52.6)
History
Duration of Asthma (years), median (IQR) 6 (4–13)
Hemoptysis, No. (%) 86 (36.8)
Expectoration of brownish black mucous
plugs, No. (%)
93 (39.7)
Cigarette smoking, No. (%) 14 (6)
History of anti-tuberculous therapy, No. (%) 95 (40.6)
Spirometry, No. (%)
Normal 55 (23.5)
Mild obstruction 59 (25.2)
Moderate obstruction 75 (32.1)
Severe obstruction 45 (19.2)
Bronchodilator reversibility 103 (44)
Serological findings
Aspergillus skin test, No. (%)
Type I 234 (100)
Type III 181 (77.4)
Absolute eosinophil count (cells/mL), median (IQR) 847 (480–1551)
Aspergillus precipitins, No. (%) 194 (82.9)
Total IgE levels (IU/mL), median (IQR) 5015 (2839–10000)
A fumigatus specific IgE levels (kUA/L), median (IQR) 4.6 (1.4–16.1)
HRCT findings, No. (%)
Normal 55 (23.5)
Central bronchiectasis 179 (76.5)
No. of lobes, median (IQR) 3 (2–4)
No. of segments, median (IQR) 7 (5–10)
Other radiologic findings (pulmonary fibrosis,
bleb, bullae, pneumothorax, parenchymal scarring,
emphysematous change, multiple cyst,
fibrocavitary lesions and pleural thickening)
27 (11.5)
Centrilobular nodules and/or tree-in-bud opacities 69 (29.5)
High attenuation mucus 49 (20.9)
doi:10.1371/journal.pone.0015346.t001
Figure 1. Presence of central bronchiectasis in two different patients with allergic bronchopulmonary aspergillosis. The presence of
classic signet ring appearance of dilated bronchi is easily appreciable (arrows). The bronchiectasis is located predominantly in the inner half of the
lung fields.
doi:10.1371/journal.pone.0015346.g001
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considered if the mucus was visually denser than the normal
paraspinal skeletal muscle and the corresponding CT attenuation
values were noted.[12,24] Other radiologic findings (ORF) such as
pulmonary fibrosis, bleb, bullae, pneumothorax, parenchymal
scarring, emphysematous change, multiple cyst, fibrocavitary
lesions and pleural thickening proposed by Kumar et al. were
recorded.[15] Based on the HRCT findings the patients were
classified according to the following schemes:
(a) Greenberger classification: ABPA-S and ABPA-CB[14]
(b) Kumar classification: ABPA-S, ABPA-CB and ABPA-CB-
ORF[15]
(c) Classification based on HAM: ABPA-S, ABPA-CB and
ABPA-CB-HAM
The patients were treated with glucocorticoids and followed up
with history and physical examination, chest radiograph and total
IgE levels every six weeks.[2] Treatment response was classified as
remission, if the IgE levels declined by .35% and there was clinical/
radiological improvement after three months of glucocorticoids or
relapse if there was a doubling of baseline IgE levels with
clinicoradiological worsening. Patients with two or more relapses
wereclassifiedasfrequentrelapseswhereasthosewithnoorone relapse
were categorized as infrequent relapses. For the purpose of this study,
we evaluated the clinical and serological severity in the three
radiological classifications, and the factors predicting frequent
relapses. To ascertain the clinical significance of various classifica-
tions, we systematically excluded patients with HAM, CB and ORF
from each of the classifications and then re-analyzed the severity.
Statistical analysis
Data are presented as mean (SD), median (IQR) or number
(percentage). Statistical significance was assumed at a p-value of
less than 0.05. The differences between continuous variables were
analyzed using student’s t-test, Mann-Whitney U test, ANOVA
(with Scheffe’s test for post hoc analysis) or Kruskal-Waalis test
(with Dwass-Steel-Critchlow-Fligner test for post hoc analysis) as
appropriate. Categorical variables were compared using the chi-
square test. A multivariate logistic regression analysis was
performed to determine the CT findings predicting frequent
relapses.
Results
There were 123 males and 111 females with a mean (SD) age of
34.1 (12.5) years. The baseline characteristics of these patients are
shown in Table 1. The median duration of asthma was six years
with the recognition of ABPA being generally delayed. In fact,
40.6% of patients had inappropriately received antitubercular
therapy in the past. Fifty-five (23.5%) patients had a normal
HRCT (ABPA-S) and 179 (76.5%) had CB (ABPA-CB) (Figure 1).
Forty-nine (20.9%) patients were identified to have HAM
impaction on HRCT chest (Figure 2) at presentation whereas 27
(11.5%) patients had ORF (Figure 3). Three patients had HAM
involving a single lobe whereas the remaining had multilobar
involvement. The density measurements are available in only 15
patients and ranged from 108 to 168 Hounsfield units.
Greenberger classification
The clinical features, spirometry and serological findings as per
the Greenberger classification is shown in Table 2. The A fumigatus
specific IgE levels and eosinophil counts but not the total IgE levels
were higher in ABPA-CB compared to ABPA-S. However, the
serological severity varied once patients with HAM and ORF were
excluded from the analysis. On removal of ORF, both A
fumigatus specific IgE levels and eosinophil counts remained
Figure 2. High-resolution computed tomographic images of patients with allergic bronchopulmonary aspergillosis demonstrating
the presence of high-attenuation mucus. (A) Mediastinal window showing the presence of hyperattenuated mucus within dilated bronchi. The
mucus is denser than the paraspinal skeletal muscle (asterisk) (B) Lung window shows that hyperdense mucus can occasionally be appreciated even
with the parenchymal sections (circle); (C) CT Hounsfield values of mucus in dilated bronchi: mucus in the left lung is hyperdense with higher CT
attenuation values compared to mucoid impaction in the right lung; (d) Hyperattenuated (bold arrow) and normal attenuation mucus (thin arrow) in
the same mediastinal window.
doi:10.1371/journal.pone.0015346.g002
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retained significance (Table 2). The clinical history and the
spirometry findings were similar in the two groups. The numbers
of relapses were higher in the CB group irrespective of the
presence or absence of HAM and ORF.
Kumar classification
On classifying the patients according to the Kumar classification
(Table 3), the clinical history and spirometric findings were similar
in the three groups. The total IgE levels were statistically
insignificant between the groups. The A fumigatus specific IgE
levels and eosinophil counts were significantly different between
the groups. On post hoc analysis, the A fumigatus specific IgE levels
were higher in ABPA-CB vs. ABPA-S and the eosinophil counts
were higher in ABPA-CB compared to the other two groups
(ABPA-S and ABPA-CB-ORF). Once patients with HAM
were excluded, only the eosinophil counts retained significance
in patients with ABPA-CB compared to ABPA-S and ABPA-CB-
ORF. The number of relapses were higher in both ABPA-CB and
ABPA-CB-ORF compared to ABPA-S, but was not different
between ABPA-CB and ABPA-CB-ORF.
New classification based on HAM
On classifying patients based on HAM (Table 4), the eosinophil
counts and the IgE levels (total and A fumigatus specific) were higher
in ABPA-CB-HAM compared to both ABPA-S and ABPA-CB,
and remained significant even after exclusion of patients with
ORF (Table 5). The clinical history and the spirometric findings
were similar in the three groups. The numbers of relapses were not
only higher in both ABPA-CB and ABPA-CB-HAM compared to
ABPA-S but were also higher in ABPA-CB-HAM vs. ABPA-CB.
Impact of serological and CT findings on frequent
relapses
There was clinical and radiological improvement in all the
patients receiving glucocorticoid therapy. The mean (SD) duration
of follow-up was 31.1 (17.6) months. 138 (59%) patients
experienced relapse of ABPA with the median (range) relapses
being 1 (0–7). There were 97 (41.5%) patients with frequent
relapses. On multivariate logistic regression analysis, the factors
predicting frequent relapses were presence of HAM and CB after
adjusting for other CT finding of ORF (Table 5).
Discussion
The results of this study suggest that HRCT chest findings
correlate with immunological severity in ABPA, and the most
consistent marker of serological severity was HAM. The
classification of ABPA based on other criteria was inconsistent
with some features being severe in one classification but not in the
Figure 3. Other radiological features (ORF) that are encountered in patients with allergic bronchopulmonary aspergillosis:
(A) parenchymal fibrosis involving the right lower lobe; (B) parenchymal and pleural fibrosis; (C) aspergilloma within a bronchiectatic cavity; (D) large
cavity with air fluid level; (E) multiple bulla with central bronchiectasis; (F) left sided pneumothorax- numerous bronchiectatic cavities can be
appreciated in the collapsed lung.
doi:10.1371/journal.pone.0015346.g003
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independent predictors of recurrent relapses.
The Rosenberg-Patterson criteria (Table 6) are most frequently
used in the diagnosis of ABPA.[3,4] However, there is lack of
consensus on the number of criteria required for diagnosis or the
specific cut-off values for the various tests utilized in diagnosis.[34]
An immediate cutaneous hypersensitivity to A fumigatus antigen is
the most reliable method for screening for ABPA.[5,31,35,36,37]
A positive test is virtually seen in all patients although 40% of
asthmatics without ABPA can also demonstrate skin test
positivity.[5] However, the type III and IV cutaneous reactions
do not have diagnostic or prognostic value.[2,12,25,30] The total
IgE level is another useful test in the diagnosis of ABPA, and
normal values exclude active ABPA from the work-up of patients
with respiratory symptoms. Neither the initial levels nor the
quantum decline in IgE values have any prognostic signifi-
cance.[12,25] Elevated A fumigatus specific IgG/IgE levels greater
than twice the pooled serum samples from patients with Aspergillus
hypersensitive asthma is paramount in the differential diagnosis of
ABPA from Aspergillus sensitized asthma.[30,38] Serum precipitins
to A fumigatus although present in 69–90% of patients with
ABPA,[11,12,39,40,41] are also seen in 10% of other pulmonary
disorders including asthma,[41,42,43] and thus represent support-
ive not diagnostic evidence for ABPA.
Similarly, there is no agreement on the severity classification,
and they continue to be modified and updated.[31,34] Green-
berger et al. classified ABPA into ABPA-S or ABPA-CB
respectively depending on the absence or presence of bronchiec-
tasis.[14] They proposed that patients with ABPA-S represent the
earliest stage of the disease with less severe immunologic findings
compared to ABPA-CB.[14] However, in this study only the A
fumigatus specific IgG levels and precipitins were higher in patients
with ABPA-CB.[14] The other immunologic parameters namely
total IgE and A fumigatus specific IgE were similar in the two
groups.[14] Thereafter Kumar et al. divided ABPA into three
categories and suggested that ABPA-CB-ORF represents clinically
and serologically the severest form of ABPA.[15] However, this
study had included only 18 patients (six in each group). Moreover,
the findings included in the categorization of ABPA-CB-ORF
were all changes representing the fibrotic stage of the disease. Both
the studies were limited by the sample size and the fact that the
clinical significance of these classifications was not investigated.
In this study, we evaluated the clinical and serological severity of
both these classifications using data from a large set of patients.
The classification scheme by Greenberger et al. showed immuno-
logical severity in some parameters (eosinophil count and A
fumigatus specific IgE levels) but not in others (total IgE levels).
Moreover, on excluding patients with HAM, the immunological
severity was restricted only to eosinophil counts. Interestingly, in
the Kumar classification, the immunological markers were most
severe in patients with ABPA-CB and not ABPA-CB-ORF. This
suggests that ORF does not determine serological severity and
Table 2. Clinical, spirometric, serological differences and outcomes in patients with allergic bronchopulmonary aspergillosis
(ABPA) based on the classification by Greenberger et al with and without the presence of high attenuation mucus (HAM) and other
radiologic findings (ORF).
All patients (n=234) Without HAM (n=185) Without ORF (n=207)
Characteristics
ABPA-S
(n=55)
ABPA-CB
(n=179) P value
ABPA-CB
(n=130) P value
ABPA-CB
(n=152) P value
Clinical history
Age, in years 35.9 (13.4) 33.6 (12.2) 0.23 33.9 (12.3) 0.37 34.1 (11.9) 0.36
Male Gender, No.(%) 25 (45.5) 98 (54.7) 0.23 73 (56.2) 0.18 83 (54.6) 0.24
Duration of asthma, in years 6 (5–12) 6 (4–14) 0.85 7 (4–15) 0.75 7 (4–15) 0.82
Spirometry, No.(%)
Normal 15 (27.3) 40 (22.3) 0.33 21 (16.2) 0.05 36 (23.9) 0.55
Mild obstruction 14 (25.5) 45 (25.1) 34 (26.2) 39 (25.7)
Moderate obstruction 20 (36.4) 55 (30.7) 39 (30) 48 (31.6)
Severe obstruction 6 (10.9) 39 (21.8) 36 (27.7) 29 (19.1)
Serological findings
Total IgE levels, IU/mL 3850
(2650–7800)
5400
(2859–10313)
0.07 4689
(2619–7895)
0.65 5457
(2867–10314)
0.06
A fumigatus specific IgE levels, kUA/L 2.1
(0.95–9.5)
4.8
(1.7–18)
0.02 3.4
(1.4–13.8)
0.19 5.6
(1.9–17.9)
0.01
Absolute eosinophil count, cells/mL6 2 0
(250–962)
983
(558–1770)
0.001 850
(475–1506)
0.03 1048
(650–1800)
0.0001
Type III AST, No.(%) 45 (81.8) 136 (76) 0.37 98 (75.4) 0.34 120 (79.5) 0.2
Aspergillus precipitins, No.(%) 48 (87.3) 146 (82) 0.36 103 (79.8) 0.23 117 (77) 0.46
Clinical outcome
Number of relapses 0 (0–1) 2 (0–2) 0.0001 1 (0–2) 0.004 2 (0–2) 0.0001
Frequent ($2) relapses, No. (%) 8 (14.5) 89 (49.7) 0.0001 49 (37.6) 0.002 75 (49.3) 0.0001
Values are expressed as mean (SD) or median (IQR) unless otherwise stated; ABPA-S - serologic ABPA; ABPA-CB - ABPA with central bronchiectasis.
The A fumigatus specific IgE levels and eosinophil counts were higher in ABPA-CB compared to ABPA-S. The serological severity varies once patients with HAM and ORF
are excluded. On removal of HAM (column 4), only the eosinophil counts retain significance, whereas on removal of ORF (column 6), both A fumigatus specific IgE levels
and eosinophil counts remain significant.
doi:10.1371/journal.pone.0015346.t002
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addition to evaluating these two classifications, we proposed a new
classification based on HAM.[16,44,45] The HAM classification
was the most consistent with immunological severity persisting
even after removal of patients with ORF.
High attenuation mucous plugging is described as the most
characteristic finding of ABPA.[22,46,47] The finding is attributed
either to the presence of calcium salts, iron and manganese,[48] or
desiccated mucus.[49] The association of HAM with poorer
outcomes in ABPA remains unclear, but one obvious reason is that
the higher attenuation points to a more inspissated type of mucus.
It is probable that the presence of HAM defines a subgroup of
patients with more severe inflammation. Numerous genetic
alterations have been described with ABPA,[2] and it may well
be hypothesized that patients with HAM have certain genetic
abnormalities that dictate a disease with more severe inflammation
and poorer outcomes. However, more research is needed to
investigate the exact reason for this association. There was no
specific anatomical/geometric occurrence and distribution of
HAM observed in this study. In contrast to previous series that
found HAM to be more prevalent in unilobar mucus plugging,[18]
most of our patients had multilobar hyperdense mucus plugging.
We also assessed the clinical significance of all classifications in
terms of relapse. The presence of CB was a consistent marker of
relapse in all classifications irrespective of whether patients with
HAM or ORF were included or not. Moreover, in the Kumar
classification, there was no statistical significance in the relapse
rates between ABPA-CB and ABPA-CB-ORF, suggesting that it is
the CB and not ORF that predicts relapse. However, in the HAM
classification, the relapse rates were higher in ABPA-CB-HAM
compared to ABPA-CB even after excluding patients with ORF
suggesting that HAM independently predicts relapses. Finally, this
was also confirmed in the multivariate model, wherein CB and
HAM were independent predictors of frequent relapses.
Few studies have described factors predicting outcome in
patients with ABPA. In two earlier studies, we had observed that
HAM and CB are independent markers of relapse.[12,25]
Greenberger et al. and Kumar et al. reported that patients with
ABPA-S developed fewer exacerbations and no patient progressed
to irreversible lung disease.[14,15,50] However, the studies by
Greenberger and Kumar did not include all the CT findings. Also,
these studies did not perform multivariate analysis to determine
factors predicting frequent relapses, which was performed in our
study.[14,15,50]
Table 3. Clinical, spirometric, serological differences and outcomes in patients with allergic bronchopulmonary aspergillosis
(ABPA) based on the classification by Kumar et al with and without the presence high attenuation mucus (HAM).
All patients (n=234) Without HAM (n=185)
Characteristics
ABPA-S
(n=55)
ABPA-CB
(n=152)
ABPA-CB-ORF
(n=27) P value
ABPA-CB
(n=111)
ABPA-CB-ORF
(n=19) P value
Clinical history
Age, in years 35.9 (13.4) 34.1 (11.9) 30.4 (13.7) 0.16 34.2 (11.9) 32 (14.9) 0.49
Male Gender, No.(%) 25 (45.5) 83 (54.6) 15 (55.6) 0.48 61 (55) 12 (63.2) 0.33
Duration of asthma, in years 6 (5–12) 7 (4–15) 5 (3–10) 0.18 8 (4–15) 5 (3–8) 0.08
Spirometry, No.(%)
Normal 15 (27.3) 36 (23.7) 4 (14.8) 0.21 20 (18) 3 (15.8) 0.25
Mild obstruction 14 (25.5) 39 (25.7) 6 (22.2) 30 (27) 4 (21.1)
Moderate obstruction 20 (36.4) 48 (31.6) 7 (25.9) 34 (30.6) 5 (26.3)
Severe obstruction 6 (10.9) 29 (19.1) 10 (37) 27(24.3) 7 (36.8)
Serological findings
Total IgE levels, IU/mL 3850
(2650–7800)
5457
(2867–10314)
5400
(2320–10220)
0.18 4588
(2500–7860)
5800
(2659–11000)
0.36
A fumigatus specific IgE levels,
kUA/L
2.1
(0.95–9.5)
5.6
(1.9–17.9)
c
2.3
(1.4–18.3)
0.03 3.9
(1.4–13)
1.6
(1.1–18.3)
0.35
Absolute eosinophil count,
cells/mL
620
(250–962)
1048
(650–1800)
c,d
450
(200–985)
0.0001 983
(593–1540)
c,d
370
(161–650)
0.0001
Type III AST, No.(%) 45 (81.8) 117 (77) 19 (70.4) 0.5 84 (75.7) 14 (73.7) 0.62
Aspergillus precipitins, No.(%) 48 (87.3) 120 (79.5) 26 (96.3) 0.06 85 (77.3) 18 (94.7) 0.09
Clinical outcome
Number of relapses 0 (0–1) 2 (0–2)
c 2 (0–2)
a 0.0001 1 (0–2)
c 1 (0–2) 0.03
Frequent ($2) relapses, No. (%) 8 (14.5) 75 (49.3)
c 14 (51.8)
a 0.0001 42 (37.8)
c 7 (36.8)
a 0.007
Values are expressed as mean (SD) or median (IQR) unless otherwise stated; ABPA-S - serologic ABPA; ABPA-CB - ABPA with central bronchiectasis; ABPA-CB-ORF - ABPA
with CB and other radiologic findings;
aABPA-CB-ORF value significant compared to ABPA-s;
bABPA-CB-ORF value significant compared to ABPA-CB;
cABPA-CB value significant compared to ABPA-s;
dABPA-CB value significant compared to ABPA-CB-ORF;
The A fumigatus specific IgE levels and eosinophil counts, but not the total IgE levels are different between the groups (columns 1 to 3). On post hoc analysis, the A
fumigatus specific IgE levels are higher in ABPA-CB (column 2) compared to ABPA-S (column 1) and the eosinophil counts are higher in ABPA-CB (column 2) in
comparison to the other two groups (columns 1 and 3). Once HAM is excluded (columns 5 and 6), only the eosinophil counts remain significant in ABPA-CB (column 5)
compared to ABPA-S (column 1) and ABPA-CB-ORF (column 6).
doi:10.1371/journal.pone.0015346.t003
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numerous aspects, although it does contain majority of patients
from these previous studies.[12,25,30] The outcome used for
defining relapses is different from our previous reports.[12,30]
Previously, we had defined relapse as doubling of the baseline IgE
levels irrespective of the patient’s symptoms or appearance of
radiological opacities.[12,25,30] However, we have observed that
doubling of IgE levels could also occur non-specifically and hence
in this study we have used a definition that includes doubling of
IgE levels as well as clinicoradiological worsening. Another
Table 4. Clinical, spirometric, serological differences and outcomes in patients with allergic bronchopulmonary aspergillosis
(ABPA) based on the proposed staging on the basis of high attenuation mucus (HAM) with and without the presence of other
radiologic findings (ORF).
All patients (n=234) Without ORF (n=207)
Characteristics
ABPA-S
(n=55)
ABPA-CB
(n=130)
ABPA-CB-HAM
(n=49) P value
ABPA-CB
(n=107)
ABPA-CB- HAM
(n=45) P value
Clinical history
Age, in years 35.9 (13.4) 33.9 (12.3) 32.6 (12) 0.33 34.6 (11.9) 33 (11.9) 0.37
Male Gender, No.(%) 25 (45.5) 73 (56.2) 25 (51) 0.4 59 (55.1) 24 (53.3) 0.5
Duration of asthma, in years 6 (5–12) 7 (4–15) 5 (3–11) 0.28 7 (4–15) 5 (3.5–12) 0.27
Spirometry, No.(%)
Normal 15 (27.3) 21 (16.2) 10 (20.4) 0.25 19 (17.8) 10 (22.2) 0.48
Mild obstruction 14 (25.5) 34 (26.2) 11 (22.4) 29 (27.6) 10 (22.2)
Moderate obstruction 20 (36.4) 39 (30) 16 (32.7) 33 (30.8) 15 (33.3)
Severe obstruction 6 (10.9) 36 (27.7) 12 (24.5) 26 (24.3) 10 (22.2)
Serological findings
Total IgE levels, IU/mL 3850
(2650–7800)
4689
(2619–7895)
10220
(5310–12200)
a, b
0.0001 4590
(2698–7860)
10314
(5556–12435)
a, b
0.0001
A fumigatus specific IgE levels, kUA/L 2.1 (0.95–9.5) 3.4 (1.4–13.8) 7.8 (4.7–23.7)
a, b 0.0001 3.9 (1.4–13) 9.3 (4.7–23.9)
a, b 0.0001
Absolute eosinophil count, cells/mL6 2 0
(250–962)
850
(475–1506)
1200
(800–2506)
a, b
0.0001 983
(593–1540)
1200
(824–2056)
a, b
0.0001
Type III AST, No.(%) 45 (81.8) 98 (75.4) 38 (77.6) 0.63 82 (76.6) 35 (77.8) 0.75
Aspergillus precipitins, No.(%) 48 (87.3) 103 (79.8) 43 (87.8) 0.3 81 (76.4) 39 (86.7) 0.15
Clinical outcome
Number of relapses 0 (0–1) 1 (0–2)
c 3 (2–3)
a,b 0.0001 1 (0–2)
c 3 (2–3)
a,b 0.0001
Frequent ($2) relapses, No. (%) 8 (14.5) 49 (37.7)
c 40 (81.6)
a,b 0.0001 39 (36.4)
c 36 (80)
a,b 0.0001
Values are expressed as mean (SD) or median (IQR) unless otherwise stated; ABPA-S - serologic ABPA; ABPA-CB - ABPA with central bronchiectasis;
aABPA-CB-HAM value significant compared to ABPA-s;
bABPA-CB-HAM value significant compared to ABPA-CB;
cABPA-CB value significant compared to ABPA-s;
dABPA-CB value significant compared to ABPA-HAM.
doi:10.1371/journal.pone.0015346.t004
Table 5. Effects of HRCT findings (HAM, number of
bronchiectatic segments and ORF) on occurrence of frequent
relapses - multivariate logistic regression model.
Variables
Adjusted odds ratio
(95% confidence intervals) P value
High-attenuation mucus 6.86 (3.03 to 15.52) 0.0001
Other radiologic findings 1.34 (0.56 to 3.21) 0.505
Central bronchiectasis 3.41 (1.45 to 8.01) 0.005
Constant 1.043 0.901
doi:10.1371/journal.pone.0015346.t005
Table 6. Rosenberg-Patterson criteria for the diagnosis of
allergic bronchopulmonary aspergillosis [3,4].
Major criteria
N Bronchial asthma
N Immediate cutaneous hypersensitivity to A fumigatus antigen
N Serum total IgE levels (.1000 IU/mL)
N Serum A fumigatus specific IgG and/or IgE levels more than twice the
mean plus two standard deviation values in patients with Aspergillus
hypersensitive asthma
N Central bronchiectasis on HRCT chest
N Serum precipitins against A fumigatus
N Fleeting or fixed pulmonary opacities on chest radiograph
N Peripheral blood eosinophil count .1000 cells/mL
Minor criteria
N Sputum cultures demonstrating growth of A fumigatus
N Expectoration of brownish-black mucus plugs
N Type III skin reactions to A fumigatus antigen
The presence of six out eight major criteria makes the diagnosis almost certain.
doi:10.1371/journal.pone.0015346.t006
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15346important difference is the definition of ORF used in this study. In
our previous study, we had defined ORF as that originally
described by Kumar et al. plus other CT features such as
centrilobular nodules, tree-in-bud opacities and HAM.[30]
However, in this study the definition of ORF is strictly retained
as defined by Kumar et al.[15] This strict compartmentalization
has been performed to clearly ascertain the significance of ORF
vis-a `-vis HAM in defining the radiological severity and their
significance in ABPA. Finally the multivariate regression model in
this study includes only CT findings and not serological findings,
because we had previously demonstrated that serological findings
do not predict clinical outcome.[12,25]
What are the clinical implications of this study? Based on the
results of this study, a patient with ABPA and hyperattenuated
mucus at diagnosis represents an immunologically severe disease
with increased propensity of recurrent relapses. Whether these
group of patients require more intensive treatment protocols or
closer monitoring remains to be answered. Hence, HAM should
be incorporated in the classification of ABPA. These conclusions
are valid and particularly relevant, not only because of the large
sample size and long duration of follow-up, but also due to the fact
that we analyzed the clinical, serological and long-term outcomes
in terms of relapses.
In conclusion, the classification scheme based on high
attenuation mucus most consistently predicts immunological
severity in ABPA. CB and HAM are independent predictors of
frequent relapses in ABPA. Hence, HAM should be employed in
the radiological classification of ABPA.
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